ArticleNature communications2024
Acetyl-DL-leucine in two individuals with REM sleep behavior disorder improves symptoms, reverses loss of striatal dopamine-transporter binding and stabilizes pathological metabolic brain pattern-case reports.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Disease-Modifying, Neuroprotective Effect of N-Acetyl-l-Leucine in Adult and Pediatric Patients With Niemann-Pick Disease Type C.Neurology · 2025Trial
- Synthesis of N-Acetyl-D- and -L-Leucine-ChemMedChem · 2026Article
- N-acetyl-L-leucine in Neurological Disorders: Mechanisms, Evidence, and Therapeutic Perspectives.Cerebellum (London, England) · 2026Review
- N-acetyl-l-leucine lowers α-synuclein levels and improves synaptic function in Parkinson's disease models.The Journal of clinical investigation · 2026Article
- Gait dysfunction as an early marker of phenoconversion in REM sleep behavior disorder.Scientific reports · 2026Article
- Lifestyle medicine in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Relationships between immune cells, blood metabolites, and intrahepatic cholangiocarcinoma: a Mendelian randomization study with experimental validation.Frontiers in cell and developmental biology · 2026Article
- Metabolomic and immunophenotypic signatures in cerebral amyloid angiopathy: a pilot study.Scientific reports · 2025Article
- Patient-Derived Neurons Exhibit α-Synuclein Pathology and Previously Unrecognized Major Histocompatibility Complex Class I Elevation in Mitochondrial Membrane Protein-Associated Neurodegeneration.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- Acetyl-Leucine Improves Cerebellar Dysarthria in MSA-C.Movement disorders clinical practice · 2025Article
- Synergistic blood-based diagnostic value of AP3B1 and BMPR2 in Parkinson's disease.NPJ Parkinson's disease · 2025Article
- REM Sleep Behavior Disorder as a Prodromal Synucleinopathy: Updates on Clinical and Laboratory Biomarkers, and Implications for Neuroprotective Trials.Current neurology and neuroscience reports · 2025Review
- Acetyl-DL-leucine (Tanganil™) in three patients with advanced multiple system atrophy.BMC neurology · 2025Article
- Update on the Present and Future Pharmacologic Treatment of Parkinson's Disease.Neurology and therapy · 2025Review
- The Status of Neuroimaging with SPECT and PET in Germany: Results from the 1st Survey on Nuclear Neuroimaging in Germany in 2023.Nuklearmedizin. Nuclear medicine · 2025Article
- Novel technologies for REM sleep behavior disorder detection for home screening in Parkinson's disease and related alpha-synucleinopathies.NPJ Parkinson's disease · 2025Article
- "How to save a marriage": treatment of REM sleep behavior disorder (RBD) with acetyl-leucine in a patient with Parkinson's disease.Journal of neurology · 2025Article
- Fully automatic categorical analysis of striatal subregions in dopamine transporter SPECT using a convolutional neural network.Annals of nuclear medicine · 2025Article
- Tourette syndrome: effects of acetyl-leucine in two individuals.Journal of neurology · 2025Article
- Precision neuroscience.Nature biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Isolated REM Sleep Behavior Disorder (iRBD) is considered a prodrome of Parkinson's disease (PD). We investigate whether the potentially disease-modifying compound acetyl-DL-leucine (ADLL; 5 g/d) has an effect on prodromal PD progression in 2 iRBD-patients. Outcome parameters are RBD-severity sum-score (RBD-SS-3), dopamine-transporter single-photon emission computerized tomography (DAT-SPECT) and metabolic "Parkinson-Disease-related-Pattern (PDRP)"-z-score in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.